Infigratinib (BGJ398)

別名:NVP-BGJ398

Infigratinib (BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM in cell-free assays, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2.

Infigratinib (BGJ398)化学構造

CAS No. 872511-34-7

サイズ 価格(税別) 在庫状況
JPY 22000 国内在庫あり
JPY 29500 国内在庫あり
JPY 40500 国内在庫あり
JPY 85500 国内在庫あり
JPY 145500 国内在庫なし(納期7~10日)

代表番号: 045-509-1970|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(218)

製品安全説明書

現在のバッチを見る: 純度: 99.9%
99.9

Infigratinib (BGJ398)と併用されることが多い化合物

Rivaroxaban


Infigratinib coadministration with Rivaroxaban may potentially result in a clinically significant in vivo metabolic DDI.

Tang LWT, et al. J Pharmacol Exp Ther. 2022 Aug;382(2):123-134.

Bevacizumab (anti-VEGF)


Infigratinib and Bevacizumab exert a synergistic inhibitory effect on tumor growth, invasion, and lung metastasis in mice bearing FGFR-dependent HCC.

Le TBU, et al. Int J Mol Sci. 2020 Dec 10;21(24):9405.

Varlitinib


Infigratinib and Varlitinib show a potent antitumor effect and can effectively overcome infigratinib resistance.

Prawira A, et al. J Cancer Res Clin Oncol. 2021 Oct;147(10):2955-2968.

SAR131675


Infigratinib and SAR131675 completely inhibit lymphangiogenesis and significantly suppress tumor growth and progression in lymphatic endothelial cells (LECs).

Peng M, et al. J Gastroenterol. 2023 Sep;58(9):908-924.

Infigratinib (BGJ398)関連製品

シグナル伝達経路

FGFR阻害剤の選択性比較

Cell Data

Cell Lines Assay Type Concentration Incubation Time 活性情報 PMID
SNU-C1 Growth Inhibition Assay 0.5-5 μM 48/72 h no effect 24135816
HCT116 Growth Inhibition Assay 0.5-5 μM 48/72 h decreases cell viability 24135816
HCD9 Growth Inhibition Assay 0.5-5 μM 48/72 h decreases cell viability 24135816
HCC Growth Inhibition Assay 1-2500 nM 48 h IC50=1124 nm 25688743
HCC Growth Inhibition Assay 1-2500 nM 48 h IC50= 2359 nm 25688743
LS174T Growth Inhibition Assay 48 h IC50=4 μM 24503538
RKO Growth Inhibition Assay 48 h IC50=1.2 μM 24503538
HKH2 Growth Inhibition Assay 48 h IC50=4 μM 24503538
HCT116 Growth Inhibition Assay 48 h IC50=3 μM 24503538
sf9 Function assay 60 mins Inhibition of non-phosphorylated N-terminal His6-tagged FGFR4 C552A mutant (G442 to E753 residues) (unknown origin) expressed in sf9 cells using 5-Fluo-Ahx-KKKKEEIYFFFG-NH2 as substrate after 60 mins by microfluidic mobility shift assay, IC50 = 0.00082 μM. ChEMBL
sf9 Function assay 60 mins Inhibition of wild type non-phosphorylated N-terminal His6-tagged FGFR4 (G442 to E753 residues) (unknown origin) expressed in sf9 cells using 5-Fluo-Ahx-KKKKEEIYFFFG-NH2 as substrate after 60 mins by microfluidic mobility shift assay, IC50 = 0.062 μM. ChEMBL
sf9 Function assay 60 mins Inhibition of non-phosphorylated N-terminal His6-tagged FGFR4 C477A mutant (G442 to E753 residues) (unknown origin) expressed in sf9 cells using 5-Fluo-Ahx-KKKKEEIYFFFG-NH2 as substrate after 60 mins by microfluidic mobility shift assay, IC50 = 0.064 μM. ChEMBL
SPAC1S Growth Inhibition Assay IC50=3.19 ± 0.93 μM 23443805
MFE296 Growth Inhibition Assay IC50=2.86 ± 0.20 μM 23443805
HEC155 Growth Inhibition Assay IC50=4.74 ± 1.09 μM 23443805
AN3CA Growth Inhibition Assay IC50=1.00 ± 0.20 μM 23443805
MFE280 Growth Inhibition Assay IC50=2.63 ± 0.82 μM 23443805
RL952 Growth Inhibition Assay IC50=3.41 ± 0.23 μM 23443805
EN1 Growth Inhibition Assay IC50=4.75 ± 0.62 μM 23443805
SNGII Growth Inhibition Assay IC50=4.29 ± 0.58 μM 23443805
ISHIKAWA Growth Inhibition Assay IC50=5.48 ± 0.03 μM 23443805
HEC1A Growth Inhibition Assay IC50=10.00 ± 1.00 μM 23443805
KLE Growth Inhibition Assay IC50=3.03 ± 0.11 μM 23443805
SNGM Growth Inhibition Assay IC50=5.00 ± 0.41 μM 23443805
USPC2 Growth Inhibition Assay IC50=7.00 ± 0.21 μM 23443805
EN Growth Inhibition Assay IC50=6.03 ± 0.31 μM 23443805
MFE319 Growth Inhibition Assay IC50=5.37 ± 0.03 μM 23443805
EFE184 Growth Inhibition Assay IC50=8.04 ± 0.69 μM 23443805
ECC1 Growth Inhibition Assay IC50=6.74 ± 0.59 μM 23443805
HEC1B Growth Inhibition Assay IC50=6.45 ± 0.67 μM 23443805
USPC1 Growth Inhibition Assay IC50=5.75 ± 0.50 μM 23443805
SPAC1L Growth Inhibition Assay IC50=4.92 ± 0.50 μM 23443805
HCC827 Function assay Displacement of [3H]-cyclopamine from SMO V404M mutant in gefitinib resistant human HCC827 cells by scintillation counting, Ki = 0.0465 μM. 28787156
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明 Infigratinib (BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM in cell-free assays, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2.
Targets
FGFR1 [1]
(Cell-free assay)
FGFR3 [1]
(Cell-free assay)
FGFR2 [1]
(Cell-free assay)
FGFR3 (K650E) [1]
(Cell-free assay)
FGFR4 [1]
(Cell-free assay)
0.9 nM 1.0 nM 1.4 nM 4.9 nM 60 nM
In Vitro
In vitro BGJ398 also prevents VEGFR2 with low potency. The IC50 of BGJ398 for inhibiting VEGFR2 is 0.18 μM. BGJ398 suppresses other kinases including ABL, FYN, KIT, LCK, LYN and YES with IC50 of 2.3 μM, 1.9 μM, 0.75 μM, 2.5 μM, 0.3 μM and 1.1 μM, respectively. At the cellular level, BGJ398 inhibits the proliferation of the FGFR1-, FGFR2-Q, and FGFR3-dependent BaF3 cells with IC50 of 2.9 μM, 2.0 μM and 2 μM, respectively. BGJ398 interferes with autophosphorylation on specific tyrosine residues including FGFR-WT, FGFR2-WT, FGFR3-K650E, FGFR3-S249C and FGFR4-WT with IC50 of 4.6 nM, 4.9 nM, 5 nM, 5 nM and 168 nM, respectively. BGJ398 suppresses proliferation of the cancer cells with wild-type (WT) FGFR3 overexpression such as RT112, RT4, SW780 and JMSU1 with IC50 of 5 nM, 30 nM, 32 nM and 15 nM, respectively. [1]
Kinase Assay Radiometric kinase assay
The enzymatic kinase activity is assessed by measuring the phosphorylation of a synthetic substrate by the purified GST-fusion FGFR3-K650E kinase domain, in the presence of radiolabeled ATP. Enzyme activities are measured by mixing 10 μL of a 3-fold concentrated BGJ398 solution or control with 10 μL of the corresponding substrate mixture (peptidic substrate, ATP and [γ33P]ATP). The reactions are initiated by addition of 10 μL of a 3-fold concentrated solution of the enzyme in assay buffer. The final concentrations of the assay components are as following: 10 ng of GST-FGFR3-K650E, 20 mM Tris-HCl, pH 7.5, 3 mM MnCl2, 3 mM MgCl2, 1 mM DTT, 250 μg/mL PEG 20000, 2 μg/mL poly(EY) 4:1, 1% DMSO and 0.5 μM ATP (γ-[33P]-ATP 0.1 μCi). The assay is carried out according to the filter binding (FB) method in 96-well plates at room temperature for 10 minutes in a final volume of 30 μL including BGJ398. The enzymatic reactions are stopped by the addition of 20 μL of 125 mM EDTA, and the incorporation of 33P into the polypeptidic substrates is quantified as following: 30 μL of the stopped reaction mixture are transferred onto Immobilon-PVDF membranes previously soaked for 5 minutes with methanol, rinsed with water, soaked for 5 min with 0.5% H3PO4, and mounted on vacuum manifold with disconnected vacuum source. After spotting, vacuum is connected, and each well rinsed with 0.5% H3PO4 (200 μL). Free membranes are removed and ished four times on a shaker with 1% H3PO4 and once with ethanol. Membranes are dried and overlaid with addition of 10 μL/well of a scintillation fluid. The plates are eventually sealed and counted in a microplate scintillation counter. IC50 values are calculated by linear regression analysis of the percentage inhibition of the BGJ398.
細胞実験 細胞株 Murine BaF3 cell lines
濃度 0 μM-0.1 μM
反応時間 48 hours
実験の流れ Murine BaF3 cell lines, whose proliferation and survival has been rendered IL-3-independent by stable transduction with tyrosine kinases activated either by mutation or fusion with a dimerizing partner, are cultured in RPMI-1640 media supplemented with 10% FBS, 4.5 g/L glucose, 1.5 g/L sodium bicarbonate, and Pen/Strep. Cells are passaged twice weekly. BGJ398-mediated inhibition of BaF3 cell proliferation and viability is assessed using a Luciferase bioluminescent assay. Exponentially growing BaF3 or BaF3 Tel-TK cells are seeded into 384-well plates (4250 cells/well) at 50 μL/well using a μFill liquid dispenser in fresh medium. BGJ398 is serially diluted in DMSO and arrayed in a polypropylene 384-well plate. Then 50 nL of BGJ398 are transferred into the plates containing the cells by using the pintool transfer device, and the plates incubated at 37 °C (5% CO2) for 48 hours. Then 25 μL of Bright-Glo are added, and luminescence is quantified using an Analyst-GT. Custom curve-fitting software is used to produce a logistic fit of percent cell viability as a function of the logarithm of inhibitor concentration. The IC50 value is determined as the concentration of BGJ398 needed to reduce cell viability to 50% of a DMSO control.
実験結果図 Methods Biomarkers 結果図 PMID
Western blot pFGFR1 / FGFR1 / pFRS2 / FRS2 / MEK / ERK p-YAP (S127) / YAP Mcl-1 Cyclin D1 / Cyclin A / Cyclin B / γ-H2AX / Cleaved caspase-9 / PARP Snail / Slug / ZEB1 p-FRS2 / FRS2 / p-AKT / AKT / p-ERK / ERK 28255027
Immunofluorescence YAP 26826125
Growth inhibition assay Cell viability IC50 28255027
In Vivo
In Vivo In this orthotopic xenograft bladder cancer model, BGJ398 induces tumor growth inhibition and stasis after oral administration for 12 consecutive days at the doses of 10 and 30 mg/kg, respectively. Interestingly, the animals that received BGJ398 exhibits either no body weight loss (10 mg/kg) or 10% body weight gain (30 mg/kg), a further indication of efficacy. RT112 tumor-bearing and female Rowett rats receive a single oral administration of the monophosphate salt of BGJ398 at the doses of 4.25 and 8.51 mg/kg. BGJ398 significantly decreases the levels of pFRS2 and pMAPK in a dose-dependent manner. BGJ398 inhibits significantly bFGF-stimulated angiogenesis in a dose-dependent manner. However, BGJ398 does not impair VEGF-induced blood vessel formation. [1]
動物実験 動物モデル Athymic nude-nu mice bearing parental RT112 cell line
投与量 10 mg/kg/qd and 30 mg/kg/qd
投与経路 Oral administration
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03510455 Terminated
Tumor-Induced Osteomalacia|Oncogenic Osteomalacia
National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC)
February 27 2019 Phase 2
NCT02312804 Withdrawn
Cancer of Cervix|Tumors
The University of Texas Health Science Center at San Antonio
January 2015 Phase 1
NCT02160041 Terminated
Solid Tumor|Hematologic Malignancies
Novartis Pharmaceuticals|Novartis
July 24 2014 Phase 2
NCT01928459 Completed
Advanced Solid Tumors|Metastatic Solid Tumors
Novartis Pharmaceuticals|Novartis
October 2013 Phase 1
NCT01004224 Completed
Advanced Solid Tumors With Alterations of FGFR1 2 and or 3|Squamous Lung Cancer With FGFR1 Amplification|Bladder Cancer With FGFR3 Mutation or Fusion|Advanced Solid Tumors With FGFR1 Amplication|Advanced Solid Tumors With FGFR2 Amplication|Advanced Solid Tumors With FGFR3 Mutation
Novartis Pharmaceuticals|Novartis
December 11 2009 Phase 1

化学情報

分子量 560.48 化学式

C26H31Cl2N7O3

CAS No. 872511-34-7 SDF Download Infigratinib (BGJ398) SDFをダウンロードする
Smiles CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
保管

In vitro
Batch:

DMSO : 27 mg/mL ( (48.17 mM); Warmed with 50℃ water bath; 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください

よくある質問(FAQ)

質問1:
If you have any suggestions about the formulation of this compound for a direct oral gavage administration?

回答
BGJ398 (S2183) can be dissolved in 30% PEG400/0.5% Tween80/5% Propylene glycol at 30 mg/ml as a suspension.

Tags: Infigratinib (BGJ398)を買う | Infigratinib (BGJ398) ic50 | Infigratinib (BGJ398)供給者 | Infigratinib (BGJ398)を購入する | Infigratinib (BGJ398)費用 | Infigratinib (BGJ398)生産者 | オーダーInfigratinib (BGJ398) | Infigratinib (BGJ398)化学構造 | Infigratinib (BGJ398)分子量 | Infigratinib (BGJ398)代理店